Changes in Beneficial Ownership · 4
Exicure, Inc.
XCURNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
primary_doc.xml
Filing details
- Report period
- 2026-06-23
- Issuer
- EXICURE, INC.
- Issuer CIK
- 0001698530
- Trading symbol
- XCUR
Reporting owner 1
- Name
- Exicure HiTron Inc.
- Reporting owner CIK
- 0002046701
- Relationship
- 10% owner
- Address
- 99-13 MASAN-GIL, MIYANG-MYEON, ANSEONG-SI, GYEONGGI-DO, MALAYSIA, N8, 17601
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common | 2026-06-23 | J · Form 4[F1] | 129,183 | A | 4.5 | 1,728,130 | D |
| Common | 2026-06-24 | J · Form 4[F1] | 123,456 | A | 4.5 | 1,851,586 | D |
| Common | 2026-06-26 | J · Form 4[F1] | 253,195 | A | 4.5 | 2,104,781 | D |
| Common | 2026-07-08 | J · Form 4[F1] | 117,441 | A | 4.5 | 2,222,224 | D |
Table key
- J · Form 4
- Other acquisition or disposition; see explanation
- A
- Acquired
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership |
|---|---|---|
| Common | 1,598,947 | D |
Table key
- D
- Direct
Footnotes
- F1
- The reported acquisitions under Table I above resulted from the return of shares to the reporting person pursuant to share transfer amendment agreements entered into with certain transferees that previously acquired shares from the reporting person. Pursuant to such amendment agreements, the parties agreed to reduce the number of shares transferred under the original transactions and return shares to the reporting person. Voting and dispositive power with respect to the returned shares reverted to the reporting person only upon the transfer agent recording the returned shares in the reporting person's name.↩ 1↩ 2↩ 3↩ 4
Signature 1
- Signed
- /s/ Jang Yun Sik
- Date
- 2026-07-16
Company context
Exicure, Inc. (Nasdaq: XCUR) is a biotechnology company focused on advancing innovative healthcare technologies and pursuing strategic growth opportunities. The Company’s portfolio includes a clinical-stage program targeting stem cell mobilization for multiple myeloma, sickle cell disease, and cell and gene therapy applications. Exicure is expanding its strategic focus to include medical device technologies designed to address unmet needs in Parkinson’s disease and other healthcare markets.